XM does not provide services to residents of the United States of America.

XM does not provide services to residents of the United States of America.
R
R

Regeneron

News

Reuters - 2 weeks ago

Regeneron climbs on Q2 results beat

BUZZ-Regeneron climbs on Q2 results beat ** Drugmaker Regeneron's REGN.O shares rise ~1.8% to $1,098.47 ** Co reports Q2 adj. profit of $11.56/shr vs est. of $10.61/shr - LSEG data ** Posts quarterly revenue of $3.55 bln vs est. of $3.38 bln ** Stock up 25% YTD Reporting by Christy Santhosh
R
Reuters - 2 weeks ago

Regeneron Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Regeneron Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary Regeneron Pharmaceuticals Inc REGN.OQ reported quarterly adjusted earnings of $11.56​​ per share for the quarter ended in June, higher than the same quarter last year, when the company reported EPS of $10.24. The mean expectation of twenty four analysts for the quarter was for earnings of $10.61 per share.
R
Reuters - 2 weeks ago

Regeneron beats quarterly results on strong demand for eczema, eye treatments

Regeneron beats quarterly results on strong demand for eczema, eye treatments Aug 1 (Reuters) - Drugmaker Regeneron Pharmaceuticals REGN.O exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs. The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs.
B
R
R
S
Reuters - 2 weeks ago

Regeneron Q2 Adjusted EPS USD 11.56 Vs. IBES Estimate USD 10.6

BRIEF-Regeneron Q2 Adjusted EPS USD 11.56 Vs. IBES Estimate USD 10.6 Aug 01 (Reuters) - Regeneron Q2 EPS USD 12.41. Q2 revenue USD 3,550 million vs. IBES estimate USD 3,379 million outlook FY capex USD 750-820 million
R
Reuters - 2 weeks ago

Fed nods to cut, chips rebound, BoE up next

MORNING BID AMERICAS-Fed nods to cut, chips rebound, BoE up next A look at the day ahead in U.S. and global markets from Mike Dolan The Federal Reserve left Wall Street with little doubt about a first U.S. interest rate cut in seven weeks' time, but multiple cross-currents from the earnings season , Japan and China, and domestic politics all make for a noisy start to August.
A
A
A
B
C
G
I
N
R
U
X
M
J
U
U
U
F
E
W
A
M
Reuters - 2 weeks ago

Cencora raises annual profit forecast on strong demand for specialty medicines

Cencora raises annual profit forecast on strong demand for specialty medicines July 31 (Reuters) - Cencora COR.N raised its annual profit forecast again on Wednesday, driven by strong demand for high-priced specialty medicines that treat complex diseases such as cancer. The drug distributor also beat Wall Street estimates for third-quarter profit and revenue helped by strength in its U.S.
R
Reuters - 2 weeks ago

Regeneron Pharmaceuticals Inc <REGN.OQ> expected to post earnings of $10.61 a share - Earnings Preview

Regeneron Pharmaceuticals Inc expected to post earnings of $10.61 a share - Earnings Preview Regeneron Pharmaceuticals Inc REGN.OQ REGN.O is expected to show a rise in quarterly revenue when it reports results on August 1 for the period ending June 30 2024 The Tarrytown New York-based company is expected to report a 7.0% increase in revenue to $3.379 billion from $3.16 billion a year ago, according to the mean estimate from 22 analysts, based on LSEG data.
R
Reuters - 2 weeks ago

BioNTech rises after cancer therapy meets goal in mid-stage study

REFILE-BUZZ-BioNTech rises after cancer therapy meets goal in mid-stage study Corrects to add "$" sign in first bullet ** U.S. listed shares of BioNTech 22UAy.DE , BNTX.O rise 2.17% to $88.49 ** Co says its experimental mRNA cancer immunotherapy BNT111 in combination with Regeneron's REGN.O cancer drug Libtayo met the main goal in a mid-stage trial
P
R
Reuters - 3 weeks ago

Sanofi lifts 2024 profit forecast on strength in Dupixent, new products

UPDATE 2-Sanofi lifts 2024 profit forecast on strength in Dupixent, new products Adds share movement and analyst comment in paragraph 3, background on Roche and AstraZeneca in paragraph 4 By Manas Mishra July 25 (Reuters) - Sanofi SASY.PA on Thursday raised its full-year profit outlook after strong demand for blockbuster asthma drug Dupixent and better-than-expected sales of new launches helped its second-quarter results beat estimates.
A
R
S
Reuters - 3 weeks ago

Sanofi bumps up full-year forecast after strong Q2 profit

Sanofi bumps up full-year forecast after strong Q2 profit July 25 (Reuters) - Sanofi's SASY.PA second-quarter profit rose 3.2% on strong demand for its blockbuster asthma drug Dupixent and better-than-expected sales of new launches, with the company now expecting a stable full-year profit compared to a prior forecast of a fall. Operating income, excluding one-off items, rose 3.2% to 2.81 billion euros ($3.05 billion), above the 2.08 billion euros expected on average by analysts in a poll on the
A
R
S
Reuters - 3 weeks ago

Roche lifts 2024 profit guidance on strong drug sales

UPDATE 2-Roche lifts 2024 profit guidance on strong drug sales First-half operating profit growth beats analyst estimates Revenue from eye drug Vabysmo nearly doubles, beats estimates Expects close to 10% adjusted profit growth, up vs previous Shares traded near 1-year high earlier on Thursday Adds details on eye drug in paragraphs 5 and 7, details on CEO's strategy in last two paragraphs By Ludwig Burger FRANKFURT, July 25 (Reuters) - Roche ROG.S on Thursday raised its full-year earnings foreca
A
B
R
R
S
Reuters - 3 weeks ago

Court weighs what US must prove in Regeneron kickback case

Court weighs what US must prove in Regeneron kickback case By Nate Raymond July 22 (Reuters) - The U.S. Department of Justice on Monday urged a federal appeals court to overturn a judge's ruling that made it tougher for the government to win a lawsuit against Regeneron Pharmaceuticals REGN.O and prove the drugmaker engaged in an illegal kickback scheme.
R
T
Reuters - 1 month ago

Regeneron Pharmaceuticals Says Results For Q2 To Include Acquired In-Process Research & Development Charge Of About $24 Mln On A Pre-Tax Basis

BRIEF-Regeneron Pharmaceuticals Says Results For Q2 To Include Acquired In-Process Research & Development Charge Of About $24 Mln On A Pre-Tax Basis July 8 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O : REGENERON PHARMACEUTICALS INC - RESULTS FOR Q2 TO INCLUDE ACQUIRED IN-PROCESS RESEARCH & DEVELOPMENT CHARGE OF ABOUT $24 MILLION ON A PRE-TAX B
R
Reuters - 1 month ago

Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT

BUZZ - Nasdaq top and bottom performing stocks at about 03:45 p.m. EDT Nasdaq 100 .NDX Top Performers Percent Change Tesla Inc TSLA.OQ +6.5% NVIDIA Corp NVDA.OQ +4.6% Broadcom Inc AVGO.OQ +4.3% Micron Technology Inc MU.OQ +3.2% Arm Holdings PLC ARM.OQ +2.9% Bottom Performers Percent Change Walgreens Boots Alliance Inc WBA.OQ -4.1% Gilead Sciences Inc GILD.OQ -2.6% Regeneron Pharmaceuticals Inc REGN.OQ -2.0% Biogen Inc BIIB.OQ -1.8% O'Reilly Automotive Inc ORLY.OQ -1.6% The Nasdaq 100 .NDX gained
B
B
G
M
N
R
T
W
U
Reuters - 1 month ago

EU approves Sanofi's Dupixent for 'smoker's lungs'

EU approves Sanofi's Dupixent for 'smoker's lungs' July 3 (Reuters) - Sanofi SASY.PA and partner Regeneron REGN.O on Wednesday won European Union approval for wider use of their Dupixent injection in patients with a chronic lung disease, a rare case of the EU clearing a drug faster than the United States. The EU Commission approved Dupixent to treat chronic obstructive pulmonary disease (COPD) in patients that cannot be helped by standard inhaled drugs, Sanofi said in a statement, following a re
R
S
Reuters - 1 month ago

US drugmakers fall as Biden urges price cuts on obesity drugs

BUZZ-US drugmakers fall as Biden urges price cuts on obesity drugs ** Shares of U.S. drugmakers down between 1% and 2% after President Joe Biden and Senator Bernie Sanders, in an opinion piece on USA Today, called out Eli Lilly LLY.N and Novo Nordisk NOVOb.CO to reduce high costs of their weight loss drugs ** They also pointed to high prices of all medicines across the United States compared to other nations ** U.S.
A
G
P
R
Reuters - 2 months ago

Verona prices lung disease therapy above expectations at $2,950/month

UPDATE 3-Verona prices lung disease therapy above expectations at $2,950/month Adds company comment in paragraph 6 By Pratik Jain June 27 (Reuters) - Verona Pharma VRNA.O said on Thursday its therapy for a chronic and potentially fatal lung disease will have a wholesale price of $2,950 per month, above the estimated cost-effectiveness range by a drug-pricing watchdog.
R
S
Reuters - 2 months ago

US FDA approves Verona Pharma's inhaled COPD therapy

UPDATE 2-US FDA approves Verona Pharma's inhaled COPD therapy Adds shares, adds analyst comment in paragraphs 9 and 10, management comment in paragraph 11 By Pratik Jain and Sruthi Narasimha Chari June 26 (Reuters) - The U.S. Food and Drug Administration has granted approval to a treatment from Verona Pharma VRNA.O for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday.
R
S
Reuters - 2 months ago

FDA approves Verona Pharma's therapy for 'smoker's lungs'

FDA approves Verona Pharma's therapy for 'smoker's lungs' June 26 (Reuters) - The U.S. Food and Drug Administration has given its approval for a treatment from Verona Pharma VRNA.O for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday. Reporting by Pratik Jain and Sruthi Narasimha Chari in Bengaluru; Edi
R
S
Reuters - 2 months ago

Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia

Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia By Michael Erman NEW YORK, June 26 (Reuters) - A top Bayer BAYGn.DE pharmaceutical executive said on Wednesday his group will continue slashing managerial jobs this year, planning cuts in Germany, Japan, the United Kingdom, Belgium and the Netherlands as part of the company's internal reorganization.
B
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.